Pancreatic Cancer: New Combination shows promise

Dr. Abou-Alfa is studying a new combination, exatecon and gemcitabine in pancreatic cancer. Working at Memorial Sloan-Kettering Cancer center significant anti – tumor activity was noted.[P] Of 39 patients 69% had positive results. There were 2 complete responses, 4 partial responses and 19 patients with stable disease. [P] Reference: Abstract #141 14th Annual EORTC – AACR – NCI Conference No. 19-22, 2002.

Webmaster

June 16, 2003